Solexa developed the next-generation sequencing (NGS) technology that has become the most widely adopted in the industry, and has helped to transform life science and clinical research. The company was founded with funding from Abingworth and completed a reverse takeover of Lynx Therapeutics in March 2005. Subsequently, it was acquired by Illumina for $600 million in January 2007.